You earned this before I ever signed it.
Rapid Risk Reduction Seen in First Months The study found that semaglutide was associated with a 38% reduced risk of major adverse cardiovascular events (MACE) within the first 3 months compared to placebo (36 vs 58, respectively) Within the first 6 months, semaglutide was associated with a 41% reduced risk of MACE compared to placebo (67 vs 113, respectively) Notably, at 3 and 6 months, most patients had not yet lost much weight and many were not yet on the full target dose of semaglutide 2.4 mg weekly
Most patients see noticeable weight loss within 1-2 months
Exercise, like strength training and cardio, preserves lean muscle, boosts metabolism, and lowers risks like high cholesterol or diabetes
This feature was exploited for selective and sensitive quantification of creatinine (CRN) which is an important diagnostic parameter
Key findings from the Phase 2 Randomised Controlled Trial: Adults with obesity receiving the highest 12 mg dose lost an average of 24.2 percent body weight at 48 weeks